Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin

Victor A. Gault, Finbarr O’Harte, Patrick Harriott, +3

Diabetologia

Metabolic SyndromeInsulin SignalingBiochemistryMedicineInsulin Management +12

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity

BD Green, MH Mooney, Nigel Irwin, +3

Journal of Endocrinology

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid

BD Green, Victor A. Gault, Peter R. Flatt, +3

Archives of Biochemistry and Biophysics

Camp ProductionBiochemistryMedicineDiabetesPhysiology +6

Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential

BD Green, Nigel Irwin, Peter R. Flatt

Peptides

Insulin-releasing ActivityPituitary GlandBiochemistryAntidiabetic PotentialMedicine +6

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo

BD Green, MH Mooney, Nigel Irwin, +3

Journal of Molecular Endocrinology

Glucose-lowering ActionGlycobiologyBiological ActivitiesInsulin SignalingGastrointestinal Peptide Hormone +18

Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin (9–39)

BD Green, MH Mooney, Victor A. Gault, +6

Metabolism

Molecular PharmacologyBiochemistryNatural SciencesMedicinePeptide Library +8

Chronic treatment with exendin(9–39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice

BD Green, Nigel Irwin, Victor A. Gault, +3

Journal of Endocrinology

ImmunologyPeptide TherapeuticsGlucose ToleranceInsulin SignalingGastrointestinal Peptide Hormone +20

Metabolic Stability, Receptor Binding, cAMP Generation, Insulin Secretion and Antihyperglycaemic Activity of Novel N-Terminal Glu9-Substituted Analogues of Glucagon-Like Peptide-1

BD Green, Victor A. Gault, Nigel Irwin, +6

Biological Chemistry

Function of a long‐term, GLP‐1‐treated, insulin‐secreting cell line is improved by preventing DPP IV‐mediated degradation of GLP‐1

BD Green, H. K. Liu, Jane T. McCluskey, +4

Diabetes Obesity and Metabolism

Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3–42) and GLP-1(9–36)amide, on insulin secretion and glucose homeostasis in ob/ob mice

Jeremy C. Parker, Kerry S. Lavery, Nigel Irwin, +6

Journal of Endocrinology